In The Netherlands, since September 2003, a legal medicinal cannabis product, constituting the whole range of cannabinoids, is available for clinical research, drug development strategies, and on prescription for patients. To date, this policy, initiated by the Dutch Government, has not yet led to the desired outcome; the amount of initiated clinical research is less than expected and only a minority of patients resorts to the legal product. This review aims to discuss the background for the introduction of legal medicinal cannabis in The Netherlands, the past years of Dutch clinical experience in oncology practice, possible reasons underlying the current outcome, and future perspectives.

Additional Metadata
Keywords Cancer, Cannabinoids, Drug development, Medicinal cannabis, Oncology
Persistent URL dx.doi.org/10.1016/j.ejca.2007.09.010, hdl.handle.net/1765/36350
Citation
Engels, F.K., de Jonge, M.J.A., Mathijssen, A.H.J., Erkens, J.A., Herings, R.M.C., & Verweij, J.. (2007). Medicinal cannabis in oncology. European Journal of Cancer, 43(18), 2638–2644. doi:10.1016/j.ejca.2007.09.010